Systemic Juvenile Idiopathic Arthritis Therapeutic Pipeline Discussed in Global Markets Direct Study Available at MarketPublishers.com

27 Feb 2014 • by Natalie Aster

LONDON – Systemic juvenile idiopathic arthritis (SJIA, and formerly termed Still's disease) is a subset of juvenile idiopathic arthritis, describing patients with rash, fever, varying degrees of arthritis alongside other specific features. Accounting for just around 10% of all JIA types of, SJIA has high levels of morbidity versus other disease subtypes.

The ultimate objectives of SJIA treatment are to stop or control the damage to joints, to prevent loss of joint function, as well as to decrease pain. Patients with this chronic disease have periods of remission and flare-ups; therefore, treatment is directed at inducing remission with the least toxicity from drugs with the aim of inducing a permanent remission. Optimal treatment of patients with SJIA requires a complex approach of both pharmacologic and non-pharmacologic therapies, with drug classes used including biologicals, NSAIDs, and conventional corticosteroids and disease-modifying antirheumatic drugs (DMARDs).

Topical research report “Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014” prepared by Global Markets Direct provides an insightful analysis of the worldwide therapeutic scenario for systemic juvenile idiopathic arthritis. The study reviews the SJIA products under development by companies and different research organisations; examines the products being in various phases of development – from discovery till registration; reviews pipeline projects based on monotherapy and combined therapeutics; analyses the SJIA pipeline with respect to route of administration and molecule type; identifies the discontinued projects, alongside examining the forces that drove them from pipeline. In addition, the emerging market players with potentially strong product line are highlighted, and the most recent news and deals pertaining to the products are addressed in the study.

Major medications discussed include: Abatacept (marketed as Orencia), golimumab (Simponi), givinostat (originally ITF2357), etanercept biosimilar(Enbrel), and adalimumab biosimilar(Humira).

Report Details:

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014
Published: January, 2014
Pages: 67
Price: US$ 2,000.00

Other Diseases Pipeline Reviews H1 2014 by Global Markets Direct Include:

More topical research reports by the publisher can be found at Global Markets Direct page.

CONTACTS

The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com 
MarketPublishers.com